(Q33291861)

25 July 2017

1 reference

title

Guidance for the treatment of neovascular age-related macular degeneration (English)

1 reference

25 July 2017

1 reference

Ursula Schmidt-Erfurth

1

object named as

Ursula M Schmidt-Erfurth

1 reference

25 July 2017

5

Francesco Bandello

1 reference

25 July 2017

2

Gisbert Richard

1 reference

25 July 2017

Albert Augustin

3

1 reference

25 July 2017

William G Aylward

4

1 reference

25 July 2017

Borja Corcòstegui

6

1 reference

25 July 2017

José Cunha-Vaz

7

1 reference

25 July 2017

Alain Gaudric

8

1 reference

25 July 2017

Anita Leys

9

1 reference

25 July 2017

Rainier O Schlingemann

10

1 reference

25 July 2017

European Society for Retina Specialists' Guidelines Committee (EURETINA)

11

1 reference

25 July 2017

publication date

1 August 2007

1 reference

25 July 2017

1 reference

25 July 2017

volume

85

1 reference

25 July 2017

issue

5

1 reference

25 July 2017

page(s)

486-494

1 reference

Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Bevacizumab in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0420.2007.00979.X

10.1111/J.1600-0420.2007.00979.X

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference